Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Pittcon Organizing ... of Food Safety Tech , an e-Journal and producer ... an agreement for the second year for the co-location of ... 2014. The partnership provides that the registration fee to attend ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Two champions of science, technology, engineering, and ... annual competition for middle and high school students designed ... study. The competition presents students with real-world problems experienced ... Mathematics, and Sciences is a program administered by ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... Nov. 10, 2010 Celsion Corporation (Nasdaq: ... that is leveraging its heat sensitive liposomal platform to ... announced that it has changed  the date and time ... Veteran,s Day Holiday on November 11, 2010.  The SEC,s ...
... Biodesix Inc. announced today that the company has ... existing investors. The Series C round, which included 5 ... company,s first product VeriStrat®, a serum proteomic test that ... lung cancer (NSCLC). Existing shareholders of the company provided ...
... StemCellRegenMed, Inc. announces that a new stem cell gene ... month old child with Tay-Sachs disease on November 2, 2010. ... parents of Jewish heritage and in very rare cases families ... U.S.A. The children appear normal at birth but about six ...
Cached Biology Technology:Celsion Announces Date and Time Change for Third Quarter 2010 Financial Results Conference Call to Monday, November 15, 2010 2Biodesix Completes Series C Financing and Receives Grant 2Biodesix Completes Series C Financing and Receives Grant 3Tay-Sachs Disease Stem Cell Gene Enzyme Treatment 2
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
(Date:4/17/2014)... France have hit on a novel method to ... correct and most effective treatment possible., Kidney stones ... and developing world. If left untreated, apart from ... failure and other complications. In many patients treated ... a more effective pathological approach to diagnosis and ...
(Date:4/17/2014)... stark warning on the possible effects of gases such ... times that of carbon dioxide. Now a team of ... fully regenerable electron acceptors which helps explain why large ... being released to the atmosphere. However, there are worries ... into a vicious cycle to release large amounts of ...
Breaking Biology News(10 mins):East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... material -- in particular, dog fecal material -- may constitute ... wintertime air, says a new University of Colorado Boulder study. ... Midwestern cities in the experiment, two cities had significant quantities ... being the most likely source. "We found unexpectedly ...
... life-saving to have a warning sign before a structural system ... size, having a sign that,s easy to read is a challenge. ... University of Pennsylvania and Duke University bioengineers and chemists, such warning ... The study was conducted by professor Daniel Hammer ...
... Women and men experience pain, particularly chronic pain, ... pain also differs between women and men. While it ... analgesics are more effective in women than men, the ... Narcotic analgesics decrease pain by activating opioid receptors, which ...
Cached Biology News:New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 2New CU-Boulder study reveals bacteria from dog feces in outdoor air of urbanized air 3Penn molecular scientists develop color-changing stress sensor 2Penn molecular scientists develop color-changing stress sensor 3SUNY Downstate researchers identify possible new targets for treating pain in women 2
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... for determining the absolute count of CD34+ ... peripheral blood samples, and leukapheresis samples. These ... cell count and a total CD45 (leucocyte) ... use in the BD Procount progenitor cell ...
... 2HCl White to off-white ... inhibitor. Inhibits translation by causing premature ... DNA fragmentation in thymocytes and in ... ≥98% by TLC. Soluble in ...
... NOBLE BSA-Free Stabilizer is a bovine ... It is an aqueous solution ... a MOPS buffer (3-(N-Morpholino) propanesulfonic acid), ... a combination of 0.02% methylisothiazolone and ...
Biology Products: